Table 3.

Treatment features of LISA group compared to control group in the first week of life

	LISA (n = 169)	Control (n = 155)	p-value
Surfactant
Multiple gifts	55 (32.5%)	33 (21.3%)	0.023*
≥ 1 endotracheal tube gift	35 (20.7%)	155 (100%)	< 0.001*
Initial dose (mg/kg), median (IQR)	189 (162–207)	148 (126–174)	< 0.001*
Total dose (mg/kg), median (IQR)	208 (178–329)	160 (129–198)	< 0.001*
Respiratory support
Intubation	65 (38.5%)	155 (100%)	< 0.001*
MV 12 h	60 (35.5%)	119 (76.8%)	< 0.001*
MV (days), median (IQR)	0.0 (0–1)	1.0 (1–3)	< 0.001*
Drug prescriptions
Morphine	20 (11.8%)	23 (14.8%)	0.426
Midazolam	3 (1.8%)	1 (0.6%)	0.358
Inotropes	16 (9.5%)	28 (18.1%)	0.024*
Insulin	8 (4.7%)	13 (8.4%)	0.182
Antibiotics for suspected EOS (days), median (IQR)	3 (2–6)	5 (3–7)	< 0.001*
PDA treatment courses			0.658
None	91 (53.8%)	84 (54.2%)
1	46 (27.2%)	35 (22.6%)
> 1	32 (18.9%)	36 (23.2%)
Erythrocyte transfusions			0.003*
None	127 (75.1%)	90 (58.1%)
1	23 (13.6%)	37 (23.9%)
> 1	19 (11.2%)	28 (18.1%)
Thrombocyte transfusions			0.458
None	153 (90.5%)	136 (87.7%)
1	10 (5.9%)	12 (7.7%)
> 1	6 (3.6%)	7 (4.5%)
Enteral feeding (mL/kg), median (IQR)
Day 5	88 (50–120)	60 (40–120)	0.051
Day 7	120 (80–160)	100 (60–140)	0.048*
Umbilical catheter	64 (37.9%)	80 (51.6%)	0.013*
Phototherapy (days), mean (SD)	2.1 (1.8)	2.1 (1.6)	0.826

*shows significance (p < 0.05)

MV 12 h Mechanical ventilation for more than 12 h, PDA Patent ductus arteriosus